Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Immunohistochemistry

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    714 result(s) found for: Immunohistochemistry. Displaying page 3 of 36.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-023625-38 Sponsor Protocol Number: JF003 Start Date*: 2012-11-13
    Sponsor Name:Guy's and St Thomas' NHS Foundation Trust
    Full Title: Investigating the effect of Maraviroc on microbial translocation in HIV-1 infected individuals who are receiving antiretroviral therapy
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-005118-35 Sponsor Protocol Number: LUD2003-009 Start Date*: 2005-09-26
    Sponsor Name:Ludwig Institute for Cancer Research
    Full Title: Randomized double-blind phase II trial of NY-ESO-1 ISCOMATRIX and ISCOMATRIXadjuvant alone in patients with resected stage III or IV malignant melanoma
    Medical condition: resected stage IIc, III or IV malignant melanoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025650 Malignant melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002721-37 Sponsor Protocol Number: CLBH589BDE03T Start Date*: 2009-06-09
    Sponsor Name:Medizinische Fakultät der TU-München, vertreten durch den Dekan
    Full Title: An open-label, uncontrolled phase II trial of HDAC inhibitor LBH589 in patients with chemo-refractory metastatic gastric cancer overexpressing histone deacetylases - CLBH589BDE03T
    Medical condition: A study with patients with chemo-refractory metastatic gastric cancer overexpressing histone deacetylases (HDACs)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001707-11 Sponsor Protocol Number: M06HER Start Date*: 2007-06-07
    Sponsor Name:NKI-AvL
    Full Title: Prospective, randomized, pharmacological intervention study; evaluating the effect of the angiotensin II-receptor (AT1) blocker candesartan versus placebo in prevention of trastuzumab-associated ca...
    Medical condition: WHO: 0-2 Serum creatinine <140 umol/l Thyroid stimulating hormone between 0.5-3.9 MU/l. Blood pressure systolic ≥ 140 mmHg diastolic ≥ 90 mmHg is acceptable at randomization. LVEF  50% assessed b...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002238-29 Sponsor Protocol Number: NL49479.029.14 Start Date*: 2014-12-18
    Sponsor Name:
    Full Title: Paclitaxel-trastuzumab in EGFR-mutated NSCLC patients after progression on TKI-treatment; a pilot study
    Medical condition: NSCLC with EGFR mutation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005835-87 Sponsor Protocol Number: GBG41 Start Date*: 2006-08-16
    Sponsor Name:GermanBreastGroup
    Full Title: A randomized discontinuation phase II study to determine the efficacy of RAD001 in breast cancer patients with bone metastases
    Medical condition: Bone metasatsis, Breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000074-51 Sponsor Protocol Number: GBG 39 Start Date*: 2005-05-03
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A multicenter phase II study to determine the efficacy of capecitabine as first line monochemotherapy in patients with HER2 negative, medium-risk, metastatic breast cancer
    Medical condition: patients with HER2 negative metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000112-29 Sponsor Protocol Number: LUMC202001 Start Date*: 2021-05-20
    Sponsor Name:Leiden University Medical Center
    Full Title: [18F]fluoro-PEG-folate PET/CT imaging in patients with epithelial ovarian cancer
    Medical condition: Epithelial ovarian cancer (EOC)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002947-41 Sponsor Protocol Number: N19PCA Start Date*: 2019-11-20
    Sponsor Name:Netherlands Cancer Institute- Antoni van Leeuwenhoek
    Full Title: Neoadjuvant trial on the efficacy of propranolol monotherapy in angiosarcoma (PROPANGIO).
    Medical condition: Angiosarcoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003788-13 Sponsor Protocol Number: 1013 Start Date*: 2023-09-21
    Sponsor Name:Heikki Minn
    Full Title: Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?
    Medical condition: Metastatic prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002563-22 Sponsor Protocol Number: 2020/538 Start Date*: 2021-09-13
    Sponsor Name:CHU de Besançon
    Full Title: Spartalizumab, mDCF (docetaxel, cisplatin and 5-fluorouracil) and radiotherapy in patients with metastatic squamous cell anal carcinoma. A Phase IIA study
    Medical condition: metastatic anal canal cancer
    Disease:
    Population Age: Gender:
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004190-13 Sponsor Protocol Number: TX05-03 Start Date*: 2018-02-08
    Sponsor Name:Tanvex Biologics Corp.
    Full Title: A randomized, double-blind, parallel group, Phase III trial to compare the efficacy, safety, and immunogenicity of TX05 with Herceptin® in subjects with HER2 positive early breast cancer
    Medical condition: HER-2 positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020472-34 Sponsor Protocol Number: IEO S542/310 Start Date*: 2010-12-14
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: 18F-Fluorothymidine Positron Emission Tomography as an early predictor of response to neoadjuvant therapy in patients with locally advanced breast carcinoma
    Medical condition: Breast carcinoma classified as cT1b,c, T2, T3, or cT4 a-c, cN0-2, N3, M0
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006289 HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003022-24 Sponsor Protocol Number: N19IFC Start Date*: 2019-10-15
    Sponsor Name:NKI-AVL
    Full Title: INFLUENCE (INtra-operative evaluation of a novel FLUorescENt C-mEt tracer in penile and tongue cancer)
    Medical condition: Penile cancer and tongue cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034300 Penile neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003416-30 Sponsor Protocol Number: 12175 Start Date*: 2020-12-17
    Sponsor Name:Erasmus University Medical Center
    Full Title: Guided by Light: Optimizing Surgical Excision of Oral Cancer Using Real-time Fluorescence Imaging
    Medical condition: Squamous Cell Carcinoma of the Oral Cavity
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005592-13 Sponsor Protocol Number: FERRICHFII Start Date*: 2014-02-27
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King's College Hospital NHS Foundation Trust
    Full Title: Mechanisms of Exercise Benefit with Intravenous Iron in Chronic Heart Failure: The Ferric Iron in Heart Failure (FERRIC HF) II Trial
    Medical condition: Chronic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002808-28 Sponsor Protocol Number: OZM-061 Start Date*: 2017-12-29
    Sponsor Name:Princess Margaret Cancer Centre
    Full Title: Olala Trial: A Retrospective/Prospective Analysis of Characterization of the Long-Term Responders on Olaparib in Solid Tumours
    Medical condition: epithelial ovarian cancer (including fallopian tube or peritoneal cancer)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001853-15 Sponsor Protocol Number: NL61830 Start Date*: 2018-07-11
    Sponsor Name:Leiden University Medical Center
    Full Title: An explorative study for halting inflammation in patients with emphysema by intravenous administration of autologous bone marrow derived mesenchymal stromal cells.
    Medical condition: Pulmonary emphysema
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003185-27 Sponsor Protocol Number: C17-02 Start Date*: 2018-04-18
    Sponsor Name:GERCOR
    Full Title: A non-comparative randomized 2:1 phase II study of docetaxel, cisplatin, and 5-fluorouracil in combination or not with atezolizumab in patients with metastatic or unresectable locally advanced squa...
    Medical condition: Metastatic or unresectable locally advanced squamous anal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10002141 Anal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005752-16 Sponsor Protocol Number: CR0207-22 Start Date*: 2008-03-03
    Sponsor Name:Cancer Research UK
    Full Title: A Cancer Research UK randomised phase II trial of ATN-224 (copper binding agent) in combination with exemestane versus exemestane alone in post-menopausal women with recurrent or advanced, oestroge...
    Medical condition: recurrent or advanced oestrogen and/or progesterone receptor positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006198 Breast cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 15:09:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA